RXi Pharmaceuticals Corporation, a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced the results of a consumer/functional testing program with RXI-231, a cosmetic ingredient based

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field